1. Genetics and Genomics

Maximizing CRISPRi efficacy and accessibility with dual-sgRNA libraries and optimal effectors

  1. Joseph M Replogle
  2. Jessica L Bonnar
  3. Angela N Pogson
  4. Christina R Liem
  5. Nolan K Maier
  6. Yufang Ding
  7. Baylee J Russell
  8. Xingren Wang
  9. Kun Leng
  10. Alina Guna
  11. Thomas M Norman
  12. Ryan A Pak
  13. Daniel M Ramos
  14. Michael Emmerson Ward
  15. Luke A Gilbert
  16. Martin Kampmann
  17. Jonathan S Weissman  Is a corresponding author
  18. Marco Jost  Is a corresponding author
  1. University of California, San Francisco, United States
  2. Whitehead Institute for Biomedical Research, United States
  3. Harvard Medical School, United States
  4. National Institutes of Health, United States
  5. National Institute of Neurological Disorders and Stroke, United States
https://doi.org/10.7554/eLife.81856
Share this article
Cite this article
  1. Joseph M Replogle
  2. Jessica L Bonnar
  3. Angela N Pogson
  4. Christina R Liem
  5. Nolan K Maier
  6. Yufang Ding
  7. Baylee J Russell
  8. Xingren Wang
  9. Kun Leng
  10. Alina Guna
  11. Thomas M Norman
  12. Ryan A Pak
  13. Daniel M Ramos
  14. Michael Emmerson Ward
  15. Luke A Gilbert
  16. Martin Kampmann
  17. Jonathan S Weissman
  18. Marco Jost
(2022)
Maximizing CRISPRi efficacy and accessibility with dual-sgRNA libraries and optimal effectors
eLife 11:e81856.
https://doi.org/10.7554/eLife.81856
  2. Download BibTeX
  3. Download .RIS

Abstract

CRISPR interference (CRISPRi) enables programmable, reversible, and titratable repression of gene expression (knockdown) in mammalian cells. Initial CRISPRi-mediated genetic screens have showcased the potential to address basic questions in cell biology, genetics, and biotechnology, but wider deployment of CRISPRi screening has been constrained by the large size of single guide RNA (sgRNA) libraries and challenges in generating cell models with consistent CRISPRi-mediated knockdown. Here, we present next-generation CRISPRi sgRNA libraries and effector expression constructs that enable strong and consistent knockdown across mammalian cell models. First, we combine empirical sgRNA selection with a dual-sgRNA library design to generate an ultra-compact (1-3 elements per gene), highly active CRISPRi sgRNA library. Next, we compare CRISPRi effectors to show that the recently published Zim3-dCas9 provides an excellent balance between strong on-target knockdown and minimal nonspecific effects on cell growth or the transcriptome. Finally, we engineer a suite of cell lines with stable expression of Zim3-dCas9 and robust on-target knockdown. Our results and publicly available reagents establish best practices for CRISPRi genetic screening.

Data availability

Sequencing data are available on NCBI GEO under accession number GSE205310 (Perturb-seq) and GSE205147 (bulk RNA-seq). sgRNA counts from CRISPRi screens are included as supplemental tables. All data generated or analyzed during this study are included in the manuscript and supporting files.

The following data sets were generated

Article and author information

Author details

  1. Joseph M Replogle

    Medical Scientist Training Program, University of California, San Francisco, San Francisco, United States
    Competing interests
    Joseph M Replogle, consults for Maze Therapeutics and Waypoint Bio.

  2. Jessica L Bonnar

    Whitehead Institute for Biomedical Research, Cambridge, United States
    Competing interests
    No competing interests declared.

  3. Angela N Pogson

    Whitehead Institute for Biomedical Research, Cambridge, United States
    Competing interests
    No competing interests declared.

  4. Christina R Liem

    Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, United States
    Competing interests
    No competing interests declared.

  5. Nolan K Maier

    Department of Microbiology, Harvard Medical School, Boston, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-6103-6726

  6. Yufang Ding

    Department of Microbiology, Harvard Medical School, Boston, United States
    Competing interests
    No competing interests declared.

  7. Baylee J Russell

    Department of Microbiology, Harvard Medical School, Boston, United States
    Competing interests
    No competing interests declared.

  8. Xingren Wang

    Department of Microbiology, Harvard Medical School, Boston, United States
    Competing interests
    No competing interests declared.

  9. Kun Leng

    Medical Scientist Training Program, University of California, San Francisco, San Francisco, United States
    Competing interests
    No competing interests declared.

  10. Alina Guna

    Whitehead Institute for Biomedical Research, Cambridge, United States
    Competing interests
    No competing interests declared.

  11. Thomas M Norman

    Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, United States
    Competing interests
    Thomas M Norman, consults for Maze Therapeutics. The Regents of the University of California with TMN, MJ, LAG, and JSW as inventors have filed patent applications related to CRISPRi/a screening and Perturb-seq..

  12. Ryan A Pak

    Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, United States
    Competing interests
    No competing interests declared.

  13. Daniel M Ramos

    Center for Alzheimer's Disease and Related Dementias, National Institutes of Health, Bethesda, United States
    Competing interests
    No competing interests declared.

  14. Michael Emmerson Ward

    National Institute of Neurological Disorders and Stroke, Bethesda, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5296-8051

  15. Luke A Gilbert

    Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, United States
    Competing interests
    Luke A Gilbert, declares outside interest in Chroma Medicine. The Regents of the University of California with TMN, MJ, LAG, and JSW as inventors have filed patent applications related to CRISPRi/a screening and Perturb-seq. LAG, MK, and JSW are inventors on US Patent 11,254,933 related to CRISPRi/a screening..

  16. Martin Kampmann

    Institute for Neurodegenerative Diseases, University of California, San Francisco, San Francisco, United States
    Competing interests
    Martin Kampmann, serves on the Scientific Advisory Boards of Engine Biosciences, Casma Therapeutics, Cajal Neuroscience, and Alector, and is an advisor to Modulo Bio and Recursion Therapeutics. LAG, MK, and JSW are inventors on US Patent 11,254,933 related to CRISPRi/a screening..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3819-7019

  17. Jonathan S Weissman

    Whitehead Institute for Biomedical Research, Cambridge, United States
    For correspondence
    weissman@wi.mit.edu
    Competing interests
    Jonathan S Weissman, declares outside interest in 5 AM Venture, Amgen, Chroma Medicine, KSQ Therapeutics, Maze Therapeutics, Tenaya Therapeutics, Tessera Therapeutics, and Third Rock Ventures. The Regents of the University of California with TMN, MJ, LAG, and JSW as inventors have filed patent applications related to CRISPRi/a screening and Perturb-seq. LAG, MK, and JSW are inventors on US Patent 11,254,933 related to CRISPRi/a screening..

  18. Marco Jost

    Department of Microbiology, Harvard Medical School, Boston, United States
    For correspondence
    marco_jost@hms.harvard.edu
    Competing interests
    Marco Jost, consults for Maze Therapeutics and Gate Bioscience. The Regents of the University of California with TMN, MJ, LAG, and JSW as inventors have filed patent applications related to CRISPRi/a screening and Perturb-seq..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1369-4908

Funding

National Institutes of Health (R00GM130964)

  • Marco Jost

National Institutes of Health (T32AI132120)

  • Baylee J Russell

Human Frontier Science Program (2019L/LT000858)

  • Alina Guna

Chan Zuckerberg Initiative (Ben Barres Early Career Acceleration Award)

  • Martin Kampmann

Howard Hughes Medical Institute (Investigator)

  • Jonathan S Weissman

National Institutes of Health (RM1HG009490-01)

  • Jonathan S Weissman

Springer Nature Global Grant for Gut Health (1772808)

  • Marco Jost

Charles H. Hood Foundation (Child Health Research Award)

  • Marco Jost

Defense Advanced Research Projects Agency (HR0011-19-2-0007)

  • Jonathan S Weissman

Ludwig Center for Molecular Oncology (NA)

  • Jonathan S Weissman

Chan Zuckerberg Initiative (NA)

  • Jonathan S Weissman

National Institutes of Health (F31NS115380)

  • Joseph M Replogle

National Institutes of Health (F30AG066418)

  • Kun Leng

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Metrics

  • 20,980
    views
  • 62
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Joseph M Replogle
  2. Jessica L Bonnar
  3. Angela N Pogson
  4. Christina R Liem
  5. Nolan K Maier
  6. Yufang Ding
  7. Baylee J Russell
  8. Xingren Wang
  9. Kun Leng
  10. Alina Guna
  11. Thomas M Norman
  12. Ryan A Pak
  13. Daniel M Ramos
  14. Michael Emmerson Ward
  15. Luke A Gilbert
  16. Martin Kampmann
  17. Jonathan S Weissman
  18. Marco Jost
(2022)
Maximizing CRISPRi efficacy and accessibility with dual-sgRNA libraries and optimal effectors
eLife 11:e81856.
https://doi.org/10.7554/eLife.81856

Share this article

https://doi.org/10.7554/eLife.81856

Categories and tags

Research organism

Further reading

    1. Genetics and Genomics
    2. Microbiology and Infectious Disease

    Control of pili synthesis and putrescine homeostasis in Escherichia coli

    Iti Mehta, Jacob B Hogins ... Larry Reitzer
    Research Article

    Polyamines are biologically ubiquitous cations that bind to nucleic acids, ribosomes, and phospholipids and, thereby, modulate numerous processes, including surface motility in Escherichia coli. We characterized the metabolic pathways that contribute to polyamine-dependent control of surface motility in the commonly used strain W3110 and the transcriptome of a mutant lacking a putrescine synthetic pathway that was required for surface motility. Genetic analysis showed that surface motility required type 1 pili, the simultaneous presence of two independent putrescine anabolic pathways, and modulation by putrescine transport and catabolism. An immunological assay for FimA—the major pili subunit, reverse transcription quantitative PCR of fimA, and transmission electron microscopy confirmed that pili synthesis required putrescine. Comparative RNAseq analysis of a wild type and ΔspeB mutant which exhibits impaired pili synthesis showed that the latter had fewer transcripts for pili structural genes and for fimB which codes for the phase variation recombinase that orients the fim operon promoter in the ON phase, although loss of speB did not affect the promoter orientation. Results from the RNAseq analysis also suggested (a) changes in transcripts for several transcription factor genes that affect fim operon expression, (b) compensatory mechanisms for low putrescine which implies a putrescine homeostatic network, and (c) decreased transcripts of genes for oxidative energy metabolism and iron transport which a previous genetic analysis suggests may be sufficient to account for the pili defect in putrescine synthesis mutants. We conclude that pili synthesis requires putrescine and putrescine concentration is controlled by a complex homeostatic network that includes the genes of oxidative energy metabolism.

    1. Genetics and Genomics

    UBR-1 deficiency leads to ivermectin resistance in Caenorhabditis elegans

    Yi Li, Long Gong ... Shangbang Gao
    Research Article

    Resistance to anthelmintics, particularly the macrocyclic lactone ivermectin (IVM), presents a substantial global challenge for parasite control. We found that the functional loss of an evolutionarily conserved E3 ubiquitin ligase, UBR-1, leads to IVM resistance in Caenorhabditis elegans. Multiple IVM-inhibiting activities, including viability, body size, pharyngeal pumping, and locomotion, were significantly ameliorated in various ubr-1 mutants. Interestingly, exogenous application of glutamate induces IVM resistance in wild-type animals. The sensitivity of all IVM-affected phenotypes of ubr-1 is restored by eliminating proteins associated with glutamate metabolism or signaling: GOT-1, a transaminase that converts aspartate to glutamate, and EAT-4, a vesicular glutamate transporter. We demonstrated that IVM-targeted GluCls (glutamate-gated chloride channels) are downregulated and that the IVM-mediated inhibition of serotonin-activated pharynx Ca2+ activity is diminished in ubr-1. Additionally, enhancing glutamate uptake in ubr-1 mutants through ceftriaxone completely restored their IVM sensitivity. Therefore, UBR-1 deficiency-mediated aberrant glutamate signaling leads to ivermectin resistance in C. elegans.

    1. Genetics and Genomics

    Dimeric R25CPTH(1–34) activates the parathyroid hormone-1 receptor in vitro and stimulates bone formation in osteoporotic female mice

    Minsoo Noh, Xiangguo Che ... Sihoon Lee
    Research Article

    Osteoporosis, characterized by reduced bone density and strength, increases fracture risk, pain, and limits mobility. Established therapies of parathyroid hormone (PTH) analogs effectively promote bone formation and reduce fractures in severe osteoporosis, but their use is limited by potential adverse effects. In the pursuit of safer osteoporosis treatments, we investigated R25CPTH, a PTH variant wherein the native arginine at position 25 is substituted by cysteine. These studies were prompted by our finding of high bone mineral density in a hypoparathyroidism patient with the R25C homozygous mutation, and we explored its effects on PTH type-1 receptor (PTH1R) signaling in cells and bone metabolism in mice. Our findings indicate that R25CPTH(1–84) forms dimers both intracellularly and extracellularly, and the synthetic dimeric peptide, R25CPTH(1–34), exhibits altered activity in PTH1R-mediated cyclic AMP (cAMP) response. Upon a single injection in mice, dimeric R25CPTH(1–34) induced acute calcemic and phosphaturic responses comparable to PTH(1–34). Furthermore, repeated daily injections increased calvarial bone thickness in intact mice and improved trabecular and cortical bone parameters in ovariectomized (OVX) mice, akin to PTH(1–34). The overall results reveal a capacity of a dimeric PTH peptide ligand to activate the PTH1R in vitro and in vivo as PTH, suggesting a potential path of therapeutic PTH analog development.